Literature DB >> 173799

Anti-viral activity of single-stranded homopolynucleotides against encephalomyocarditis virus and Semliki Forest virus in adult mice without interferon induction.

N Stebbing, C A Grantham, N H Carey.   

Abstract

Single administrations of poly C or poly I are anti-viral against infections of encephalomyocarditis (EMC) and Semliki Forest virus (SFV) in mice but poly U and poly A are not. The degree of protection is dose-dependent and mice which die do so at a later time when untreated controls even in a strain of mouse in which the time of death is not dependent on the dose of virus given. No circulating interferon is found after treating mice with poly C or poly I even at polynucleotide doses which give the same degree of protection as the interferon inducer, poly I:C. Several additional features distinguish the protection by poly C and poly I from interferon induction: the effect is low 24h before infection and maximal 6 h before infection, the effect is short-lived and mice do not show hypo-reactivation to repeated treatment. Limited treatment of mice with poly I:C, interferon or poly C before infection itself results in additional protection when poly C is also administered after infection, indicating that poly C has an effect after onset of virus replication. After infection poly C and poly I are both more effective by the intravenous route but before infection they are most effective when administered by the same route as the virus. Quantitative comparisons of the protective effects of poly C, poly I and the interferon inducer, poly I:C, are possible from dose response curves of the polynucleotides at different times relative to infection and by different routes of administration. The results are considered in relation to the presence of homopolyribonucleotide tracts in the viral genomes and effects on the reticulo-endothelial system of the mice.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 173799     DOI: 10.1099/0022-1317-30-1-21

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  In vivo interference in vesicular stomatitis virus infection.

Authors:  J Crick; F Brown
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

2.  Requirement for macrophages for interferon to be effective against encephalomyocarditis virus infection of mice.

Authors:  N Stebbing; K M Dawson; I J Lindley
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

3.  Anti-viral effects of single-stranded polynucleotides against avirulent Semliki Forest virus infection of mice and avirulent infection of rats with encephalomyocarditis virus.

Authors:  N Stebbing; I J Lindley
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

4.  Variations in the contribution of induced interferon and adjuvanticity to the antiviral effect of different polyinosinic acid . polycytidylic acid formulations in mice infected with encephalomyocarditis virus.

Authors:  N Stebbing; I J Lindley; K M Dawson
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

5.  The antiviral activity of ribosomal polynucleotides against encephalomyocarditis virus infection of mice.

Authors:  A G Stewart; C A Grantham; K M Dawson; N Stebbing
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

6.  Studies on the mode of action of single-stranded polynucleotides which are antiviral against encephalomyocarditis virus infection of mice.

Authors:  N Stebbing
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

7.  Antiviral activities of hybrids of two major human leukocyte interferons.

Authors:  P K Weck; S Apperson; N Stebbing; P W Gray; D Leung; H M Shepard; D V Goeddel
Journal:  Nucleic Acids Res       Date:  1981-11-25       Impact factor: 16.971

8.  Anti-viral activity against encephalomyocarditis virus and Semliki Forest virus and acute toxicity of poly I and poly C administered sequentially to mice.

Authors:  N Stebbing; C A Grantham
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.